Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2450060 | 0.85 | CA2 (0.40) | CA2TSHRALDH1A1CYP3A4TDP1 | |
| SCHEMBL7789131 | 0.82 | CA2 (0.48) | CA2TSHRALDH1A1CYP3A4TDP1 | |
| SCHEMBL18531388 | 0.79 | CA2 (0.46) | CA2TSHRALDH1A1CYP3A4TDP1 | |
| SCHEMBL15553019 | 0.78 | CYP3A4 (0.40) | CA2TSHRALDH1A1CYP3A4TDP1 | |
| SCHEMBL342111 | 0.78 | CA12 (0.41) | CA2ALDH1A1CA1LMNA | |
| SCHEMBL9419541 | 0.78 | CA2 (0.44) | CA2TSHRALDH1A1CYP3A4TDP1 | |
| SCHEMBL12805914 | 0.74 | CA2 (0.44) | CA2TSHRALDH1A1CYP3A4TDP1 | |
| SCHEMBL15238199 | 0.73 | CA2 (0.50) | CA2TSHRALDH1A1CYP3A4TDP1 | |
| SCHEMBL17363802 | 0.72 | CA2 (0.48) | CA2TSHRALDH1A1CYP3A4TDP1 | |
| SCHEMBL12788048 | 0.72 | CA2 (0.48) | CA2TSHRALDH1A1CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651875-B1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | SIKA TECH AG (CH) | 2017-08-30 | — | — | EP | claimed |
| CN-103261145-B | There is the amine of secondary aliphatic amino group | SIKA TECHNOLOGY AG (CH) | 2016-04-13 | — | — | CN | claimed |
| US-9290603-B2 | Amines having secondary aliphatic amino groups | SIKA TECHNOLOGY AG (CH) | 2016-03-22 | — | — | US | claimed |
| US-20130237681-A1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | SIKA TECHNOLOGY AG (CH) | 2013-09-12 | — | — | US | claimed |
| EP-2465842-A1 | Amines with secondary aliphatic amines | Sika Technology AG (CH) | 2012-06-20 | — | — | EP | claimed |
| US-8157950-B2 | Aldimine and composition containing aldimine | SIKA TECHNOLOGY AG (CH) | 2012-04-17 | — | — | US | claimed |
| US-20110253309-A1 | ALDIMINE AND COMPOSITION CONTAINING ALDIMINE | SIKA TECHNOLOGY AG (CH) | 2011-10-20 | — | — | US | claimed |
| EP-2194082-B1 | Aldimine and composition comprising aldimine | SIKA TECHNOLOGY AG (CH) | 2011-09-07 | — | — | EP | claimed |
| EP-2194082-A1 | Aldimine and composition comprising aldimine | Sika Technology AG (CH) | 2010-06-09 | — | — | EP | claimed |
| EP-2651875-B1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | SIKA TECH AG (CH) | 2017-08-30 | — | — | EP | disclosed |
| EP-2414418-B1 | COMPOSITION CURABLE IN TWO STAGES COMPRISING A SURFACE DEACTIVATED POLYISOCYANATE | SIKA TECH AG (CH) | 2017-08-09 | — | — | EP | disclosed |
| CN-103261145-B | There is the amine of secondary aliphatic amino group | SIKA TECHNOLOGY AG (CH) | 2016-04-13 | — | — | CN | disclosed |
| US-9290603-B2 | Amines having secondary aliphatic amino groups | SIKA TECHNOLOGY AG (CH) | 2016-03-22 | — | — | US | disclosed |
| US-9011630-B2 | Hot curing or heat-activated composition containing a surface-deactivated polyisocyanate | SIKA TECHNOLOGIES AG (CH) | 2015-04-21 | — | — | US | disclosed |
| WO-2010112536-A1 | HOT CURING OR HEAT-ACTIVATED COMPOSITION CONTAINING A SURFACE-DEACTIVATED POLYISOCYANATE | SIKA TECHNOLOGY AG (CH) | 2010-10-07 | — | — | WO | disclosed |
| EP-2236535-A1 | Humidity curing polyurethane composition being accelerated by influence of heat | Sika Technology AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| EP-2236533-A1 | Heat curing or heat activatable composition comprising a surface deactivated polyisocyanate | Sika Technology AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| EP-2236534-A1 | Composition curable in two stages comprising a surface deactivated polyisocyanate | Sika Technology AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| WO-2010063741-A1 | ALDIMINE AND COMPOSITION CONTAINING ALDIMINE | SIKA TECHNOLOGY AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| EP-2194082-A1 | Aldimine and composition comprising aldimine | Sika Technology AG (CH) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237681-A1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | AAAS, PNMT, PARG | CA2 4635/4885TSHR 4479/4885ALDH1A1 1074/4885 |
| US-20110253309-A1 | ALDIMINE AND COMPOSITION CONTAINING ALDIMINE | ALDH7A1, ALDH3A1, ADH5 | CA2 2967/4885TSHR 4863/4885ALDH1A1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.